These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 12641616

  • 1. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
    McNamara C, Grigg A, Szer J, Roberts A, Campbell L, Hoyt R, Lynch K, Juneja S.
    Clin Lab Haematol; 2003 Apr; 25(2):119-25. PubMed ID: 12641616
    [Abstract] [Full Text] [Related]

  • 2. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
    Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME.
    Blood; 2002 Jul 15; 100(2):435-41. PubMed ID: 12091333
    [Abstract] [Full Text] [Related]

  • 3. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C.
    J Manag Care Pharm; 2007 Oct 15; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M.
    Blood; 2002 May 15; 99(10):3547-53. PubMed ID: 11986206
    [Abstract] [Full Text] [Related]

  • 5. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Qiu JY, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 15; 26(1):23-6. PubMed ID: 15946504
    [Abstract] [Full Text] [Related]

  • 6. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC.
    Am J Clin Pathol; 2003 Jun 15; 119(6):833-41. PubMed ID: 12817431
    [Abstract] [Full Text] [Related]

  • 7. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.
    Br J Haematol; 2002 Sep 15; 118(3):771-7. PubMed ID: 12181044
    [Abstract] [Full Text] [Related]

  • 8. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.
    Hasserjian RP, Boecklin F, Parker S, Chase A, Dhar S, Zaiac M, Olavarria E, Lampert I, Henry K, Apperley JF, Goldman JM.
    Am J Clin Pathol; 2002 Mar 15; 117(3):360-7. PubMed ID: 11888075
    [Abstract] [Full Text] [Related]

  • 9. [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate].
    Chen ZC, You Y, Zhu XM, Li QB, Li WM, Zou P.
    Zhonghua Nei Ke Za Zhi; 2007 Dec 15; 46(12):1003-6. PubMed ID: 18478917
    [Abstract] [Full Text] [Related]

  • 10. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
    Xu Y, Wahner AE, Nguyen PL.
    Arch Pathol Lab Med; 2004 Sep 15; 128(9):980-5. PubMed ID: 15338554
    [Abstract] [Full Text] [Related]

  • 11. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cojbasić I, Macukanović-Golubović L.
    Srp Arh Celok Lek; 2010 Sep 15; 138(5-6):305-8. PubMed ID: 20607973
    [Abstract] [Full Text] [Related]

  • 12. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
    Cojbasić I, Macukanović-Golubović L.
    Vojnosanit Pregl; 2010 Oct 15; 67(10):802-6. PubMed ID: 21061842
    [Abstract] [Full Text] [Related]

  • 13. Imatinib: a review of its use in chronic myeloid leukaemia.
    Moen MD, McKeage K, Plosker GL, Siddiqui MA.
    Drugs; 2007 Oct 15; 67(2):299-320. PubMed ID: 17284091
    [Abstract] [Full Text] [Related]

  • 14. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
    Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J.
    Blood; 2004 Apr 15; 103(8):2873-8. PubMed ID: 15070658
    [Abstract] [Full Text] [Related]

  • 15. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Lu DP.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec 18; 37(6):612-5. PubMed ID: 16378113
    [Abstract] [Full Text] [Related]

  • 16. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.
    Med Oncol; 2004 Dec 18; 21(4):349-58. PubMed ID: 15579919
    [Abstract] [Full Text] [Related]

  • 17. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2002 Sep 18; 16(9):1579-83. PubMed ID: 12200666
    [Abstract] [Full Text] [Related]

  • 18. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
    Thiele J, Kvasnicka HM, Varus E, Ollig E, Schmitt-Graeff A, Staib P, Griesshammer M.
    Leuk Lymphoma; 2004 Aug 18; 45(8):1627-31. PubMed ID: 15370216
    [Abstract] [Full Text] [Related]

  • 19. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.
    Clin Cancer Res; 2002 Jul 18; 8(7):2177-87. PubMed ID: 12114418
    [Abstract] [Full Text] [Related]

  • 20. Initial treatment for patients with CML.
    Goldman JM.
    Hematology Am Soc Hematol Educ Program; 2009 Jul 18; ():453-60. PubMed ID: 20008231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.